Do analysts rate PCSA or VCNX?

Heatwurx currently has a consensus price target of $25.00, indicating a potential upside of 1,052.07%. Given Heatwurx's stronger consensus rating and higher probable upside, equities research analysts plainly believe Heatwurx is more favorable than Vaccinex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PCSA or VCNX more profitable?

Vaccinex's return on equity of 0.00% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -281.31% -200.80% Vaccinex N/A N/A -383.58%

Which has stronger earnings and valuation, OBSV or VCNX?

Vaccinex has higher revenue and earnings than ObsEva. Vaccinex is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ObsEva N/A N/A -$58.38M -$0.92 N/A Vaccinex $388K 6.77 -$20.25M -$48.27 N/A

Is OBSV or VCNX more profitable?

Vaccinex's return on equity of 0.00% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% Vaccinex N/A N/A -383.58%

Do analysts rate ADXN or VCNX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ADXN or VCNX more profitable?

Vaccinex's return on equity of 0.00% beat Addex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Addex Therapeutics N/A -105.98% -87.61% Vaccinex N/A N/A -383.58%

Is NKGN or VCNX more profitable?

Company Net Margins Return on Equity Return on Assets NKGen Biotech N/A N/A -479.36% Vaccinex N/A N/A -383.58%

Do analysts prefer ASBP or VCNX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, ASBP or VCNX?

Vaccinex has higher revenue and earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aspire Biopharma $10K 644.80 -$24.48M -$116.67 N/A Vaccinex $388K 6.77 -$20.25M -$48.27 N/A

Is ASBP or VCNX more profitable?

Company Net Margins Return on Equity Return on Assets Aspire Biopharma N/A N/A -398.04% Vaccinex N/A N/A -383.58%

Vaccinex (VCNX) Competitors

$1.01 -0.08 (-7.34%)

As of 03:10 PM Eastern

Compare

VCNX vs. PCSA, OBSV, ADXN, NKGN, and ASBP

Should you buy Vaccinex stock or one of its competitors? MarketBeat compares Vaccinex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vaccinex include Heatwurx (PCSA), ObsEva (OBSV), Addex Therapeutics (ADXN), NKGen Biotech (NKGN), and Aspire Biopharma (ASBP). These companies are all part of the "pharmaceutical products" industry.

How does Vaccinex compare to Heatwurx?

Heatwurx (NASDAQ:PCSA) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

91.9% of Heatwurx shares are held by institutional investors. Comparatively, 50.1% of Vaccinex shares are held by institutional investors. 2.4% of Heatwurx shares are held by insiders. Comparatively, 51.5% of Vaccinex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Heatwurx had 1 more articles in the media than Vaccinex. MarketBeat recorded 1 mentions for Heatwurx and 0 mentions for Vaccinex. Heatwurx's average media sentiment score of 1.87 beat Vaccinex's score of 0.00 indicating that Heatwurx is being referred to more favorably in the media.

Company	Overall Sentiment
Heatwurx	Very Positive
Vaccinex	Neutral

Heatwurx has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.Comparatively, Vaccinex has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

Heatwurx currently has a consensus price target of $25.00, indicating a potential upside of 1,052.07%. Given Heatwurx's stronger consensus rating and higher probable upside, equities research analysts plainly believe Heatwurx is more favorable than Vaccinex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Vaccinex's return on equity of 0.00% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-281.31%	-200.80%
Vaccinex	N/A	N/A	-383.58%

Heatwurx has higher earnings, but lower revenue than Vaccinex. Heatwurx is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A
Vaccinex	$388K	6.77	-$20.25M	-$48.27	N/A

Summary

Heatwurx beats Vaccinex on 9 of the 14 factors compared between the two stocks.

How does Vaccinex compare to ObsEva?

ObsEva (NASDAQ:OBSV) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

In the previous week, ObsEva's average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score.

Company	Overall Sentiment
ObsEva	Neutral
Vaccinex	Neutral

17.5% of ObsEva shares are held by institutional investors. Comparatively, 50.1% of Vaccinex shares are held by institutional investors. 14.4% of ObsEva shares are held by insiders. Comparatively, 51.5% of Vaccinex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Vaccinex has higher revenue and earnings than ObsEva. Vaccinex is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
Vaccinex	$388K	6.77	-$20.25M	-$48.27	N/A

ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

Vaccinex's return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Vaccinex	N/A	N/A	-383.58%

Summary

Vaccinex beats ObsEva on 6 of the 9 factors compared between the two stocks.

How does Vaccinex compare to Addex Therapeutics?

Addex Therapeutics (NASDAQ:ADXN) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Vaccinex's return on equity of 0.00% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-105.98%	-87.61%
Vaccinex	N/A	N/A	-383.58%

Addex Therapeutics has higher earnings, but lower revenue than Vaccinex. Addex Therapeutics is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	37.78	-$8.12M	-$5.74	N/A
Vaccinex	$388K	6.77	-$20.25M	-$48.27	N/A

In the previous week, Addex Therapeutics had 2 more articles in the media than Vaccinex. MarketBeat recorded 2 mentions for Addex Therapeutics and 0 mentions for Vaccinex. Addex Therapeutics' average media sentiment score of 0.39 beat Vaccinex's score of 0.00 indicating that Addex Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Addex Therapeutics	Neutral
Vaccinex	Neutral

Addex Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 50.1% of Vaccinex shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by company insiders. Comparatively, 51.5% of Vaccinex shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Addex Therapeutics beats Vaccinex on 8 of the 13 factors compared between the two stocks.

How does Vaccinex compare to NKGen Biotech?

NKGen Biotech (NYSE:NKGN) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

In the previous week, NKGen Biotech's average media sentiment score of 0.21 beat Vaccinex's score of 0.00 indicating that NKGen Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
NKGen Biotech	Neutral
Vaccinex	Neutral

NKGen Biotech has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 50.1% of Vaccinex shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by company insiders. Comparatively, 51.5% of Vaccinex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Vaccinex has higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NKGen Biotech	N/A	N/A	-$82.94M	-$1.51	N/A
Vaccinex	$388K	6.77	-$20.25M	-$48.27	N/A

Company	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
Vaccinex	N/A	N/A	-383.58%

Summary

Vaccinex beats NKGen Biotech on 5 of the 9 factors compared between the two stocks.

How does Vaccinex compare to Aspire Biopharma?

Aspire Biopharma (NASDAQ:ASBP) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

In the previous week, Aspire Biopharma had 4 more articles in the media than Vaccinex. MarketBeat recorded 4 mentions for Aspire Biopharma and 0 mentions for Vaccinex. Aspire Biopharma's average media sentiment score of 0.43 beat Vaccinex's score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Aspire Biopharma	Neutral
Vaccinex	Neutral

Vaccinex has higher revenue and earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	644.80	-$24.48M	-$116.67	N/A
Vaccinex	$388K	6.77	-$20.25M	-$48.27	N/A

19.2% of Aspire Biopharma shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 5.8% of Aspire Biopharma shares are owned by insiders. Comparatively, 51.5% of Vaccinex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aspire Biopharma has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-398.04%
Vaccinex	N/A	N/A	-383.58%

Summary

Vaccinex beats Aspire Biopharma on 8 of the 12 factors compared between the two stocks.

Get Vaccinex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCNX vs. The Competition

Export

Metric	Vaccinex	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.63M	$981.41M	$6.75B	$12.02B
Dividend Yield	N/A	4.84%	2.66%	5.61%
P/E Ratio	-0.02	0.99	20.34	22.43
Price / Sales	6.77	126.92	510.75	109.73
Price / Cash	N/A	20.06	44.01	55.64
Price / Book	-0.39	7.85	10.66	6.79
Net Income	-$20.25M	-$4.88M	$3.56B	$337.66M
7 Day Performance	1.00%	0.87%	0.05%	2.08%
1 Month Performance	-8.18%	4.71%	0.37%	3.16%
1 Year Performance	26.73%	101.84%	22.73%	27.78%

Vaccinex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCNX Vaccinex	N/A	$1.01 -7.3%	N/A	+36.8%	$2.63M	$388K	N/A	40	Gap Down
PCSA Heatwurx	4.4086 of 5 stars	$2.80 -4.1%	$25.00 +792.9%	-76.3%	$8.03M	N/A	N/A	20	Positive News Gap Down
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50
ADXN Addex Therapeutics	0.5019 of 5 stars	$6.91 +8.0%	N/A	-29.0%	$7.88M	$210K	N/A	30	Positive News Upcoming Earnings Gap Up
NKGN NKGen Biotech	N/A	$0.06 flat	N/A	-82.2%	$7.84M	N/A	N/A	N/A	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCNX) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaccinex (VCNX) Competitors

VCNX vs. PCSA, OBSV, ADXN, NKGN, and ASBP

How does Vaccinex compare to Heatwurx?

Summary

How does Vaccinex compare to ObsEva?

Summary

How does Vaccinex compare to Addex Therapeutics?

Summary

How does Vaccinex compare to NKGen Biotech?

Summary

How does Vaccinex compare to Aspire Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCNX vs. The Competition

Vaccinex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vaccinex (VCNX) Competitors

VCNX vs. PCSA, OBSV, ADXN, NKGN, and ASBP

How does Vaccinex compare to Heatwurx?

Do institutionals & insiders have more ownership in PCSA or VCNX?

Does the media favor PCSA or VCNX?

Which has more volatility & risk, PCSA or VCNX?

Do analysts rate PCSA or VCNX?

Is PCSA or VCNX more profitable?

Which has better valuation and earnings, PCSA or VCNX?

Summary

How does Vaccinex compare to ObsEva?

Does the media prefer OBSV or VCNX?

Do institutionals and insiders believe in OBSV or VCNX?

Which has stronger earnings and valuation, OBSV or VCNX?

Which has more risk and volatility, OBSV or VCNX?

Is OBSV or VCNX more profitable?

Summary

How does Vaccinex compare to Addex Therapeutics?

Do analysts rate ADXN or VCNX?

Is ADXN or VCNX more profitable?

Which has better valuation & earnings, ADXN or VCNX?

Does the media prefer ADXN or VCNX?

Which has more risk & volatility, ADXN or VCNX?

Do insiders & institutionals have more ownership in ADXN or VCNX?

Summary

How does Vaccinex compare to NKGen Biotech?

Does the media prefer NKGN or VCNX?

Which has more volatility & risk, NKGN or VCNX?

Do insiders & institutionals have more ownership in NKGN or VCNX?

Which has preferable earnings & valuation, NKGN or VCNX?

Is NKGN or VCNX more profitable?

Summary

How does Vaccinex compare to Aspire Biopharma?

Does the media prefer ASBP or VCNX?

Which has stronger valuation & earnings, ASBP or VCNX?

Do insiders and institutionals hold more shares of ASBP or VCNX?

Which has more volatility and risk, ASBP or VCNX?

Do analysts prefer ASBP or VCNX?

Is ASBP or VCNX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCNX vs. The Competition

Vaccinex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools